• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Transport of Antisense Across the Blood-Brain Barrier

        互联网

        693
        Antisense-mediated therapy holds great promise for the treatment of central nervous system (CNS) diseases in which neurodegeneration is linked to over-production of endogenous protein. Administration of antisense therapy could be difficult, however, because peripherally administered antisense would have to cross the blood-brain barrier (BBB) in effective quantities. Several studies have investigated various modifications that can be introduced into antisense molecules to improve their ability to cross the BBB. Recently, two types of unmodified antisense analogs have been shown to effectively cross the BBB and affect CNS function. One of the analogs, a phosphorothioate oligodeoxy-nucleotide (P-ODN) directed against the amyloid β protein, was peripherally administered via iv injection. This analog crosses the BBB via a saturable transport mechanism termed oligonucleotide transport system-1 (OTS-1) (1 ). Another unmodified P-ODN was also shown to cross the BBB. This P-ODN was directed at methionine enkephalin (Met-Enk), an opiate peptide associated with alcoholism (unpublished results). The second type of unmodified analog shown to cross the BBB is a peptide nucleic acid (PNA) that was directed against the neurotensin receptor NTS-1 in rats and was administered via ip injection (2 ). Antisense molecules that can cross the BBB would be potential therapeutic agents and useful tools in the elucidation of CNS pathophysiology.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序